T. Truong

发表

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial

A. Ribas, D. Moore, A. Daud, 2020, Nature Medicine.

A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer

M. Tempero, A. Ko, K. A. Jones, 2012, Cancer Chemotherapy and Pharmacology.

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134.

J. Wolchok, M. Atkins, D. Davar, 2021, Journal of Clinical Oncology.

TP53 Gain-of-Function and Non–Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer

L. Habel, M. Pan, S. Alexeeff, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.

P. Munster, C. Ryan, R. Aggarwal, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data

P. Munster, T. Truong, 2013 .

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

V. Sondak, M. Ross, M. Atkins, 2023, The New England journal of medicine.

LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)

S. Patel, M. Othus, L. Korde, 2022, Annals of Oncology.

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

J. Wolchok, M. Atkins, J. Sosman, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune-related Adverse Effects Associated with Programmed Death-1 Inhibitor Therapy in the Treatment of Non-Small Cell Lung Cancer: Incidence, Management, and Effect on Outcomes.

R. Hui, R. Cooper, F. Niu, 2020, The Permanente journal.

Role for Neutral Sphingomyelinase-2 in Tumor Necrosis Factor α-Stimulated Expression of Vascular Cell Adhesion Molecule-1 (VCAM) and Intercellular Adhesion Molecule-1 (ICAM) in Lung Epithelial Cells

Y. Hannun, C. Clarke, T. Truong, 2007, Journal of Biological Chemistry.

Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.

V. Sondak, J. Kirkwood, A. Ribas, 2022, JAMA oncology.

Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma.

V. Sondak, M. Knopp, J. Kirkwood, 2021, Cancer discovery.

25 Years of Adjuvant Therapy in Melanoma: A Perspective on Current Approvals and Insights into Future Directions

S. Patel, L. Kennedy, T. Truong, 2022, Current Oncology Reports.

Abstract CT013: S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy

J. Sosman, A. Ribas, J. Moon, 2022, Cancer Research.

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

J. Sosman, A. Ribas, P. Scumpia, 2023, Nature Medicine.

Systemic Therapy for Melanoma: ASCO Guideline Update

V. Sondak, P. Ascierto, M. Atkins, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic, clinical characteristics, and treatment outcomes of patients with metastatic castration-sensitive prostate cancer with SPOP mutations: Analysis from the Kaiser Permanente Northern California Healthcare System.

M. Pan, A. Harzstark, T. Sundaresan, 2023, Journal of Clinical Oncology.